PHARMACOKINETICS, HEMATOLOGICAL AND BIOCHEMICAL EFFECTS OF CIPROFLOXACIN HYDROCHLORIDE-SODIUM CHOLATE COMPLEX by E., Osonwa U. et al.
 
Original Article 
PHARMACOKINETICS, HEMATOLOGICAL AND BIOCHEMICAL EFFECTS OF CIPROFLOXACIN 
HYDROCHLORIDE-SODIUM CHOLATE COMPLEX 
 
OSONWA U. E.1, UGOCHUKWU J. I.2, ONYEGBULE F. A.*3, ESIMONE C. O.2 
1Department of Pharmaceutics and Pharmaceutical Technology, 2Department of Pharmaceutical Microbiology and Biotechnology, 
3Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka Nigeria 
Email: af.onyegbule@gmail.com  
Received: 19 Jan 2016 Revised and Accepted: 12 Aug 2016 
ABSTRACT  
Objective: Ciprofloxacin is a broad spectrum antibiotic widely used in the treatment of infections, but its toxicological effects remains a great 
challenge. This research emphasized on analyzing the effect of a hydrophobic ion pair complex, involving ciprofloxacin hydrochloride and sodium 
cholate and also pegylated ciprofloxacin hydrochloride-sodium cholate complex.  
Methods: The effects of ciprofloxacin-cholate complex and pegylated ciprofloxacin-cholate complex were evaluated. LD50 was determined. The test 
drugs were orally to twenty-four albino mice, in six groups of four mice, at different doses of 7.14 mg/kg, 14.2 mg/kg and 21.4 mg/kg; and PEG 
complex, 7.14 and 14.2 mg/kg. Each was administered twice daily for fourteen days. The animal blood samples were subjected to hematological, 
biochemical tests; and the liver organs were collected. Histopathological examination was carried out on the harvested organs. Pharmacokinetic 
parameters were determined using the non-compartmental method. 
Results: The LD50 of the complex was above 5000 mg/kg. The non-significant decrease in PCV and WBC showed the parent drug and its complex are 
neither anemia inducing nor immunosuppressing; the significant decrease in the average RBCs count in post–treatment of 21.47 mg/kg of the 
complex could be from physiological changes; the bio-liver makers showed hepatocellular damage. Photomicrograph of the liver sections of mice 
showed mild areas of hepatocyte degeneration and inflammatory cell infiltrates. 
Conclusion: The biochemical, hematological and histology results showed complexation did not increase adverse effects of ciprofloxacin. The 
PEGYlated complex showed higher AUC and Cmax peak than the uncomplexed drug, hence more therapeutic benefits. 
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Ciprofloxacin is a broad-spectrum antibacterial second generational 
class of fluoroquinolones that is widely used in the treatment of 
serious infections in higher animals [1]. Its chemical structure is given 
by (1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7(1-piperacinyl)-3-
quinoline carboxylic acid).  
However, according to Santo and co-workers [2], the use of 
ciprofloxacin in the treatment of infections is associated with most 
common adverse effects that include gastrointestinal tract 
disturbance, central nervous system disorder and hematological 
system disorder. According to {3}, Ciprofloxacin in the treatment of 
infections is associated with the most common adverse effects which 
include the gastrointestinal tract, central nervous system, and 
hematological system effects. Experiment using animal models and 
clinical experience also showed that Ciprofloxacin-induced 
cardiotoxicity marked by increase QT and QTC interval and 
prolonged action potential duration. This increases the risk of 
arrhythmia (tosarde de points). Ciprofloxacin-induced cardiotoxic 
effect could be associated with blocking cardiac voltage—gated 
potassium channels particularly the rapid component (IKr) of the 
delayed rectifier potassium current. Several cases of Ciprofloxacin-
induced hepatoxicity have also been reported.  
These were characterized by extensive hepatocellular necrosis, 
mixed inflammatory infiltrates and abundant eosinophils in the 
liver. Elevated liver enzymes which include serum aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, 
and gramma-glutamyltransferase and prolong prothrombin time 
were reported. The hepatotoxic effect of Ciprofloxacin as reported 
could be due to oxidative stress induced in the liver by Ciprofloxacin 
through the generation of oxidative radicals leading to depletion of 
protein content in hepatocytes as a consequence of nucleic acids 
diminution and DNA damage. This may lead to significant decrease 
in the number and degeneration in mitochondria which is 
responsible for energy supply. Ciprofloxacin-induced cardiotoxicity 
and hepatotoxicity is relatively low in humans, but patients’ liver, 
and cardiac function may be considered before Ciprofloxacin use. 
According to {4}, Ciprofloxacin decreased the sperm concentration, 
mortality, viability. These suggest that ciprofloxacin has potential 
toxicological effects on the reproductive system in male rats by 
decreased sperm count, mortality, increase apoptotic cells and 
pathological testis.  
Ciprofloxacin complexes with surfactant-based-ionic complex have 
led to a reduction in therapeutic dose [5]. This reduction in dose 
with its attendant therapeutic and toxicological advantage could be 
lost due to the possible inability of crossing the stomach barrier to 
the target site. Hence these complexes require some modifications 
using polyethylene glycol to get to the targeted site. Polyethylene 
glycol (PEG), also known as polyethylene oxide (PEO) or 
polyoxyethylene (POE), depending on its molecular weight, has low 
toxicity in the system. Its chemical structure is H-(O-CH2-CH2) n-OH. 
PEG alters solubility, thermal stability, immunogenicity and body 
residence time. This alteration may be an advantage in making 
biologically active protein suitable for therapeutic use through 
modification of pharmacokinetics and pharmacodynamics 
properties, such as prolongation of half-life in vivo or inhibition of 
degradation by proteases [6].  
This study focuses on the formation of ciprofloxacin-cholate 
complex and modifying the ciprofloxacin complex by conjugate 
chemistry, binding inert molecules such as PEG to ciprofloxacin 
cholate complex to a prolonged residence in the body and decreased 
degradation by metabolic enzymes. It also considers toxicological 
effects of the complex. 
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MATERIALS AND METHODS 
Acute toxicity study (LD50) of ciprofloxacin-cholate complex was 
measured using Lork’s method [7] 
hematological studies of ciprofloxacin and ciprofloxacin-
cholate complex and PEG complex in mice 
The experimental animals used for this study were white albino 
mice and rats of either sex. They were obtained from the Animal 
Unit of the Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe 
University, Awka. The animals were housed under standard 
conditions 25 °C+/-1 °C and 24 h light/dark cycle. They were fed 
with standard rodent pellets (Vital feed, Nigeria) and had access to 
clean drinking water. All experimental animals were in compliance 
with the National Institute of Health Guide for Care and Used of 
Laboratory Animals (Pub. No 85-23, revised 1985) [8] were adopted 
and experiments were examined and approved by the appropriate 
ethics committee” of the Faculty (Faculty of Pharmaceutical 
Sciences, Nnamdi Azikiwe University, Awka). 
The drugs (ciprofloxacin and cholate complex) were dissolved with 
distilled water (ciprofloxacin), distilled water+5 % tween 80 (for 
cholate complex) and administered orally, according to body weight, 
to sixteen white albino mice, subdivided into four groups 
having/containing four mice each. Group 1 the control was given 
only 10 ml/kg of distilled water. The test solutions were prepared 
based on the following doses: group 2 which was given 
ciprofloxacin, 7. 14 mg/kg; group 3 which was given ciprofloxacin-
cholate complex 7.14 mg/kg and group 4 was given 21.4 mg/kg. The 
dose was based on 500 mg/70 kg of body weight of a man. Each was 
administered twice daily for fourteen days (2 w). Blood samples 
collected through the pituitary eye region of animals and were 
subjected to haematological test: haemoglobin (Hb), packed cell 
volume (PCV), red blood cell (RBC), White blood cell count (WBC) 
[9], and biochemical hepatic makers: aspartate aminotransferase 
(AST), alanine aminotransferase (ALT) [10] and alkaline phosphates 
(ALP) [11]. The blood samples were kept at room temperature for 
30 min. Clear serum was separated by centrifuging at 2500 rpm for 
10 min after which the mice were sacrificed.  
Histopathological studies  
Thereafter, histopathological examination was carried out on the 
harvested organ. Tissue sections of the Liver from experimental animals 
were fixed in 10 % formalin saline and dehydrated in ascending grades 
of ethanol. Thereafter, the tissues were cleared in chloroform overnight, 
infiltrated and embedded in molten paraffin wax. The blocks were later 
trimmed and sectioned at 5–6 μm. The sections were deparaffinized in 
xylene, taken to the water and subsequently stained with Haematoxylin 
and Eosin (H and E) for light microscopy.  
Pharmacokinetics studies (Serum Concentration) of 
ciprofloxacin and ciprofloxacin-cholate complex on rats using 
bioassay 
Twenty-four rats, about 150-250 g body weight, were starved 
overnight before drug administration to avoid food-drug 
interactions. The rats were divided into six groups (A, B, C, D, E, and 
F) with each group having four rats. Respectively they were 
administered with 7.1 mg/kg CIP, 14.2 mg/kg CIP, 7.1 mg/kg 
complex, 14.2 mg/kg complex, 7.1 mg/kg complex+PEG, 14.2 mg/kg 
complex+PEG, in a single dose intraperitoneally. Samples were 
collected at sampling time 0 hr, 0.5 h, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h and 
centrifuged for 1000 rpm in 20 min to obtain serum. 
Serial dilution 100, 50, 25, 12.5, 6.25, 3.125, 1.56 µg/ml of standard 
ciprofloxacin hydrochloride was prepared; 20 ml of molten nutrient 
agar was inoculated with 0.1 ml of standardized broth culture of 
Staphylococcus aureus (obtained from Bishop Shanahan Hospital, 
Nsukka) mixed and poured into a Petri-dish (according to number of 
sampling time). A well of about 6 mm was dug in the seeded media 
plate, and 4 drops of various serum samples were introduced into 
the well along with the standard concentrations starting from the 
weakest to the strongest. Each sample was analyzed in triplicate and 
plates were allowed to stand at room temperature for about 5 min 
and incubated for 24 h at 37 °C. The IZD was measured and exact 
concentration was extrapolated using the standard curve. 
Statistical analysis 
The results were expressed as mean±Standard Deviation (SD) of 
sample replicate and paired t-test was to determine the significance 
or otherwise of the results obtained. 
RESULTS 
The result of the toxicity studies on the ciprofloxacin-cholate complex; 
effects of the ciprofloxacin-cholate complex on the packed cell volume; 
red blood cells count; haemoglobin count; white blood cells count; ALT 
level; AST level; ALP level; albumin level are presented in fig. 1 and tables 
1 to 9 respectively. Other results, such as the histopathological result of 
liver tissue are presented in A2 (in appendices). 
Histopathological result of liver tissue 
 
 
Fig. 1: Photomicrograph of liver sections of mice from 
experimental groups 1 and 3 showing mild areas of hepatocyte 
degeneration/vacuolation (white arrows) and inflammatory 
cell infiltrates (black arrows); that of groups 2 and 4 are 
apparently normal. Note the central vein (CV). H and E x 400
 
Table 1: Showing acute toxicity study (LD50) of ciprofloxacin-cholate complex on mice 
Phase 1 
Group Dosage Mice 1 Mice 2 Mice 3 
Group1 10 mg/kg ND and NST ND and NST ND and NST 
Group2 100 mg/kg ND and NST ND and NST ND and NST 
Group3 1000 mg/kg ND and NST ND and NST ND and NST 
 
Phase 2 
Group Dosage Mice 1 Mice 2 Mice 3 
Group1 2000 mg/kg ND and NST ND and NST ND and NST 
Group 2 3000 mg/kg ND and NST ND and NST ND and NST 
Group 3 4000 mg/kg ND and NST ND and NST ND and NST 
Group 4 5000 mg/kg ND and NST ND and NST ND and NST 
Key: ND =No Death; NST=No Signs of Toxicity 
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Table 2: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on packed cell volume (PCV) of albino mice 
Group Packed cell volume (%) 
Pre-administration % 
Baseline 




Complex,21.40 mg/kg 40.00±1.63 100 41.00±1.41 102 38.75±0.96 97 
Complex,7.14 mg/kg 41.75±0.96 100 43.25±0.96d 108 40.00±1.41 100 
Cipro,7.14 mg/kg 41.00±1.41 100 39.75±2.50 97 39.50±1.29 96 
Control: Distilled water, 10 ml/kg 40.50±1.26 100 40.00±2.16 99 40.25±3.10 99 
Values were expressed as mean±Standard Deviation (SD) of sample replicate, n=4. Pre-administration, Day 14th and Post-administration are 
significantly different at p<0.05.  
 
Table 3: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on red blood cell of albino mice 
Group  Red blood cell count (Cell count × 1012/l) 
Pre-administration % baseline Day 14th % baseline Post-administration % baseline 
Complex 21.40 mg/kg 10.37±0.09 100 10.55±1.90 102 8.99±0.65d 87 
Complex, 7.14 mg/kg 10.35±0.74 100 10.15±0.37 98 9.59±0.55 93 
Cipro, 7.14 mg/kg 10.41±0.08 100 10.24±0.22 98 9.83±0.42 94 
Control: Distilled water, 10 ml/kg 10.64±0.15 100 10.65±0.25 100 10.53±0.19 99 
Values were expressed as mean±Standard Deviation (SD) of sample replicate, n=4. d denotes: significantly different from pre-treatment at p<0.05. 
We used a human dose of 500 mg/kg × 2 in pharmacokinetic because it is a standard practice ant it is accepted in such treatments;  and this gives 
7.14 ×2 mg/kg. 
 
Table 4: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on haemoglobin 











Complex 21.40 mg/kg 12.85±0.68 100 12.83±0.30 100 13.38±0.89  104 
Complex, 7.14 mg/kg 13.35±0.79 100 13.18±0.75 99 13.30±1.46 100 
Cipro, 7.14 mg/kg 12.33±1.36 100 13.65±0.73 111 13.05±0.79 106 
Control: Distilled water, 10 ml/kg 13.23±0.51 100 13.13±0. 71 99 13.08±1.04 99 
Values were expressed as mean±Standard Deviation (SD) of sample replicate, n=4. Pre-administration, Day 14th and Post-administration are not 
significantly different at p<0.05. 
 
Table 5: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on white Blood cell count (WBC) of albino mice 
 White blood cell (x109/l) 
Group Pre-administration % 
Baseline 




Complex 21.40 mg/kg 8212.50±746.52 100 8962.50±453.46 109 9182.50±299.82 112 
Complex, 7.14 mg/kg 8100.00±915.61 100 8525.00±614.41 105 9412.50±359.11 116 
Cipro, 7.14 mg/kg 8175.00±698.21 100 9087.50±466.15 111 8687.50±417.08 106 
Control: Distilled water  
(10 ml/kg) 
8037.50±290.38 100 8000.00±376.39 100 8037.50±290.38 100 
Values are expressed as mean±Standard Deviation (SD) of sample replicate, n=4. Pre-administration, Day 14th and Post-administration are not 
significantly different at p<0.05.  
 
Table 6: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on alanine aminotransferase (ALT) of albino mice 
 Amino-transferase (µ/l) 
Group Pre-administration % 
Baseline 




Complex 21.40 mg/kg 45.50±4.20 100 50.75±2.50 112 44.50±4.80 98 
Complex, 7.14 mg/kg 49.75±6.85 100 52.00±1.83 105 52.00±1.83 105 
Cipro,7.14 mg/kg 40.25±1.26 100 41.50±1.29d 103 45.75±3.86d 114 
Control: Distilled water,  
10 ml/kg 
49.75±0.85 100 49.00±1.04 99 49.75±0.85 100 




The toxicity studies on the ciprofloxacin-cholate complex 
showed that the complex was not toxic 5000 mg/kg body weight 
of the experimental animal, as there was no death and no signs 
of toxicity at 5000 mg/kg. From table 2, there was no significant 
difference (P<0.05) in average packed cell volume (PCV) among 
group means except in Day 14 of 7.14 mg/kg in which case the 
complex showed a significant increase (P<0.05). In addition, 
average PCV of post-administration did not significantly differ 
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from pre-administration in all groups. However, from table 3, 
there was no significant difference (P<0.05) in average red blood 
cells among group means except in post-administration (relative 
to pre-administration) in 21.40 mg/kg complex group. Reduction 
in the red blood cells could be as a result of many factors that 
include: anaemia, bone marrow failure, nutritional deficiencies, 
malnutrition, hemolysis due to blood vessel injury and certain 
chemotherapy. 
 
Table 7: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on aspartate aminotransferase (AST) of albino mice 
 AST (µ/l) 
Group Pre-administration % 
Baseline 




Complex 21.40 mg/kg 66.75±4.57 100 61.00±1.83 91 58.00±4.32d 87 
Complex, 7.14 mg/kg 66.25±2.63 100 60.50±6.81 91  60.00±2.50d 91 
Cipro, 7.14 mg/kg 61.00±2.16 100 57.75±2.63 95 61.00±3.56 100 
Control: Distilled water,10 ml/kg 65.00±1.47 100 65.00±1.02 100 65.75±1.74 101 
Values were expressed as mean±Standard Deviation (SD) of sample replicate, n=4., ddenotes significantly different from pre-administration at 
p<0.05. 
 
Table 8: Showing effects of ciprofloxacin-cholate complex and ciprofloxacin on alkaline phosphatase (ALP) of albino mice 
 Alkaline Phosphate (µ/l) 
Group Pre-Administration % 
Baseline 




Complex 21.40 mg/kg 80.50±1.29 100 84.00±3.65 104 77.25±5.50 96 
Complex, 7.14 mg/kg 79.50±5.92 100 81.00±3.56 102 78.25±6.55 102 
Cipro, 7.14 mg/kg 75.75±5.12 100 79.75±6.55 98 77.25±4.86 102 
Control: Distilled water, 10 ml/kg 77.00±2.04 100 77.50±4.36 99 77.25±4.86 100 
Values were expressed as mean±Standard error of mean (SEM) of sample replicate (n=4). Pre-administration, Day 14th and Post-administration are 
not significantly different at p<0.05. 
 
Table 9: Serum concentration in (μg/ml) of ciprofloxacin (cipro), ciprofloxacin-cholate complex and PEG-complex in rat 












Tmax (h) 0.63±0.13 0.50±0 0±0a 0.63±0.13 0.75±0.14c 0.5±0 
Cmax (μg/ml) 1.46±0.05 1.79±0.15 0±0 1.69±0.05 1.84±0.04c 1.91±0.04 
AUC (mg/ml) 2.38±0.06 2.81±0.16 0±0a 2.44±0.11 2.9±0.09 2.45±0.34 
t ½ (h) 7.85±2.77 7.07±1.48 0±0 4.44±0.69b 5.98±2.80 6.24±2.32 
V d (ml) V VO(ml)   6.27±2.80 20.22±1.46 0±0 6.20±2.09b 4.51±1.52 18±0.64 
CL (ml/kg/h) 0.24±0.08 2.16±0.29 0±0 0.48±0.28b 0.47±0.19 2.70±0.69 
MRT (h) 1.12±0.01 1.11±0.01 0±0a 1.1±0 1.1±0 1.1±0.01 
Values are represented in mean±SEM and Values are expressed as sample replicate (n=4), aP denotes significantly different from cipro (7.14 mg/kg) 
at P<0.05, bP denotes significantly different from cipro (14.2 mg/kg) at P<0.05, cP denotes significantly different from cipro (7.14 mg/kg) at P<0.05 
CIPRO is ciprofloxacin; COMPLEX is Ciprofloxacin-cholate complex, COMPLEX+PEG is ciprofloxacin-complex with polyethylene glycol. Tmax is time taken 
for the drug to attain maximal plasma concentration. Cmax is maximal drug plasma concentration. AUC is area under the curve from the time of dosing 
to the time of the last observation. t1/2 is terminal half-life. CL is total clearance and MRT is the mean residence time. 
 
High red blood count is an indicative of dehydration, bone marrow 
or other health disorders. The significant decrease in the average 
RBCs count in post–treatment of 21.47 mg/kg of the complex could 
be as a result of physiological changes. Table 4 showed that there 
was no significant difference (P<0.05) in average haemoglobin 
among group means on day 14; average haemoglobin of post-
administration did not significantly differ from pre-administration 
and vice versa in all groups. Haemoglobin transports oxygen and 
gives the blood cell its red colour. Its concentration is directly 
proportional to its ability to transport oxygen throughout the body. 
So, non-significant difference at (P<0.05) in average haemoglobin 
among groups was indicative of sufficient oxygen. Thus the drug did 
not interfere with oxygen supply throughout the body. From table 5, 
there was no significant increase or decrease in average WBC count.  
However, average WBC of 7.14 mg/kg and 21.40 of the complex in 
post-administration increased relative to pre-administration, though 
not significant. In addition, there was a non-significant increase in 
day 14of 7.14 mg/kg of ciprofloxacin. White blood cells (Leukocytes) 
are an important part of the body’s defense against infectious 
organism and foreign substances. The non-significant decrease in 
the white blood cell is an indication that ciprofloxacin and its 
complex are not immunosuppressant. From table 6, there was a 
significant increase in average ALT level in post-administration Day 
14 relative to pre-administration (P<0.05) in ciprofloxacin group. 
ALT is present in high concentration in the cytosol of the liver and to 
a lesser extent in skeletal muscle, kidney and heart [12]. Serum ALT 
activity has been regarded as a reliable and sensitive marker of liver 
disease. When there is an increase in ALT viral or drug-induced 
hepatitis will be suspected. In addition, ALT may also be a good 
indicator of overall health such as obesity, the metabolic syndrome, 
and presence of cardiovascular disease [13]. The non-significant 
increase in average ALT level in 7.14 mg/kg and 21.4 mg/kg of the 
complex suggests the absence of hepatocellular damage and another 
health disease. However, our result showed a significant increase in 
average ALT at post administration and day 14th of 7.14 mg/kg 
ciprofloxacin group. Thus suggesting indicated a major liver 
permeability, congestion and cell rupture in ciprofloxacin group 
[14]. This result agrees with the findings of Pyriyadharshiri and 
Vanithakumari [15] that ciprofloxacin could exert a mild or high 
effect on ALT level in the serum when administered for a short or 
long duration. They also showed that enzymatic activity (ALT level) 
varies in a dose-dependent manner. From table 7, there was a 
significant decrease (dP<0.05) in Post-administration onDay 14 of 
Onyegbule et al. 
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average AST relative to Pre-administration AST in 7.14 mg/kg and 
21.40 mg/kg complex group respectively. AST is an enzyme present 
in the liver, nervous tissue, skeletal muscle, and heart. Membrane 
damages release this enzyme into circulation. High level is indicative 
of liver damage due to toxicity and viral hepatitis as well as cardiac 
infection and muscle injury [16]. Ciprofloxacin and its cholate-
complex did not have a significant increase in serum AST compared 
with pre–administration. This suggested that the integrity of the cell 
membranes of various tissues (especially the heart and liver) were 
not adversely affected. This result supports the findings of Obaleye 
and co-workers [17]. 
From table 8, there was no significant difference (P<0.05) in average 
ALP level among group means on day 14. Average ALP of post-
administration did not significantly differ from pre-administration 
and verse versa in all groups. The fact that there was no significant 
difference in serum ALP activities of Ciprofloxacin and its cholate-
complexes suggests that the integrity of the plasma membrane of the 
cells in the various tissues (bone, liver and kidney) might not have 
been adversely affected. This is because ALP is a membrane-bound 
enzyme often used to assess the integrity of the plasma membrane 
and endoplasmic reticulum. An increase in ALP activity of the serum 
implies membrane damage to the tissue [18]. 
Also, there was a significant difference (dP<0.05) in average albumin 
among group means on post-administration of 21.40 mg/kg 
complex. Average albumin level of post-administration of 21.40 
mg/kg complex significantly decreased when compared with Day 
14. Albumin reduction suggests liver disease, kidney disease or low 
protein absorption [19]. However, results of ALT, AST and ALP had 
shown no significant increase, hence, the significant decrease of 
albumin level at 21.40 mg/kg of the complex may be attributed to a 
slight side effect of high dose of the complex.  
In the histopathology, experimental groups 1, 2, 3 and 4 (control) 
were administered with 21.40 mg/kg of complex, 7.14 mg/kg of 
complex, 7.14 mg/kg of ciprofloxacin and 10 mg/ml of water 
respectively, for two weeks. Results showed that ciprofloxacin at 
dose 7.14 mg/kg and ciprofloxacin-cholate complex at dose 21.4 
mg/kg induced hepatocellular degeneration (white arrows) and 
mononuclear cell infiltration an inflammatory reaction of the 
lymphocytes and the plasma cell, (black arrows) both of which are 
reversible. Group 2 and the control were apparently normal (fig. 1).  
The pharmacokinetics analysis showed that the complex was not 
detectable in the serum at 7.14 mg/kg. This might stem from the fact 
that the percentage content of CIPRO (44.9 %) in 500 mg of the 
complex was small. In our study, pharmacokinetics parameter of 
14.2 mg/kg of CIPRO when compared to 14.2 mg/kg of complex 
showed that the complex at this dose increased the tmax from 0.5h to 
0.63hr (table 9). This showed a longer time of absorption, though it 
was negligible. The Cmax decreased from 1.79 µg/ml to 1.69 µg/ml 
and AUC from 2.8 mg/ml to 2.44 mg/ml, showing non-significant 
increases of 5.59 % and 12.9 % respectively. The decreases in the 
two parameters were indicative of poor absorption and poor 
systemic availability of the drug complex, which may affect its 
therapeutic efficacy [20]. Although the mean resident time of the 
complex remained unchanged, the half-life decreased from 7.85 hr 
to 4.44 h (43.4 %), while clearance rate changed from 2.16 ml/kg/h 
to 0.47 ml/kg/h; theoretically, ciprofloxacin half-life ranges from 3-4 
h. The decrease in half-life showed that the complex did not stay 
longer in the blood, while the decrease in clearance rate may be 
indicative of low metabolizing activity by cytochrome P450 enzymes 
in the liver [21]. The significant decrease in Vo may be indicative of 
more complex binding to the plasma protein rather than to the 
tissue [22].  
The 7.14 mg/kg CIPRO compared to 7.14 mg/kg complex+PEG 
showed that 7.14 mg/kg increased the Cmax from 1.46 µg/ml to 1.84 
µg/ml and AUC from 2.38 mg/ml to 2.9 mg/ml. Since Cmax and AUC 
are biomarkers for bioavailability [23], an increase in the two 
parameters is indicative of an enhanced absorption and good 
systemic availability. Also, there was an increase in clearance rate 
from 0.24 ml/kg/h to 0.47 ml/kg/h while the MRT remained 
unchanged. This showed a high metabolizing activity of cytochrome 
P450 enzyme in the liver [21]. The decrease in Vo (-1.56) is not far 
from its high plasma protein binding [24]. On the same hand, 14.2 
mg/kg CIPRO compared to complex+PEG at 14.2 mg/kg showed that 
tmax was constant (0.5 h), and there was an increase in Cmax (from 
1.79 µg/ml to1.91 µg/ml). This showed enhanced absorption and 
good systemic availability possibly as a result of the effect of 
polyethylene glycol on the drug, however, the AUC decreased non-
significantly. Although the half-life decreased from 7.8 h to 6.2 h 
(20.5 %), clearance rate increased from 2.16 ml/kg/h to 2.7 ml/kg/h 
along with an unchanged MRT. This result suggested a metabolic 
activity catalyzed by cytochrome P450 resident in the liver. The 
decrease in Vo from 20.22 ml to 18 ml (-2.22 ml) indicated a slight 
plasma protein-binding [24]. 
The complex at 7.14 mg/kg was detected in the serum upon addition 
of polyethylene glycol, which indicated an improved systemic 
availability of the complex at this dose. Also, the dosage of 14.2 
mg/kg showed an improved systemic availability with polyethylene 
glycol, though there was an increase in clearance and reduction in 
the half-life of the drug. The mean resident time was found to have 
little or no change while the volume of distribution showed a high 
protein binding. All these results have shown that ciprofloxacin-
cholate complex with reduced percentage of ciprofloxacin (44.9 %) 
has improved bioavailability thus effective therapeutic efficacy, 
although with the assistance of polyethylene glycol. 
Ethical approval 
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Sciences, Nnamdi Azikiwe University, Awka). 
CONCLUSION 
The LD50 of the complex was above 5000 mg/kg. The biochemical, 
hematological and histology results showed that complexation did 
not increase adverse effects of ciprofloxacin and that any such slight 
effects were reversible upon discontinuation of administration. The 
PEGYlated complex showed higher AUC peak and residence time 
than the uncomplexed drug. Thus, we could conclude that the 
PEGYlated complex would be therapeutically more beneficial than 
the uncomplexed drug. 
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